Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

Sign informed consent
Age: ≥18 years
Expected survival > or = 3months
Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease.
Agree to provide a tumor sample
Has at least one measurable lesion based on RECIST 1.1
Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1

Exclusion Criteria:

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration
Mixed small-cell lung cancer (SCLC) and NSCLC histology
Subjects with history of severe heart disease
Active autoimmune diseases and inflammatory diseases
Other malignant tumors were diagnosed within 5 years
Subjects with poorly controlled hypertension
Subjects have Grade 3 lung disease or a history of interstitial lung disease
Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring therapeutic intervention within the previous 6 months before screening
Symptoms of active central nervous system metastasis.
Subjects who have a history of allergies to recombinant humanized antibodies or human mouse chimeric antibodies or any of the components of BL-B01D1
Subjects have a history of autologous or allogeneic stem cell transplantation
Known HIV, active tuberculosis, active Hepatitis B virus infection or active Hepatitis C virus infection
Subjects with active infections requiring systemic treatment
Participated in another clinical trial within 4 weeks prior to participating in the study
Other conditions that the investigator believes that it is not suitable for participating in this clinical trial